Recent Posts
- Eyenovia To Feature Its Suite Of Commercial Products And The Optejet® Dispenser At Upcoming National Eyecare Meetings April 4, 2024
- NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals March 13, 2024
- Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th March 11, 2024
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
Eyenovia To Feature Its Suite Of Commercial Products And The Optejet® Dispenser At Upcoming National Eyecare Meetings
NewsNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NewsEyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
NewsEyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
NewsEyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
NewsEyenovia Re-Acquires Development And Commercialization Rights To Micropine In The U.S. And Canada
NewsEyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
NewsEyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NewsEyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
NewsEyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®
News